Download Sample
Schedule a Meeting
Table of Content
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global nonspecific endonuclease market was estimated at US$ 360 million in 2023 and is projected to grow to US$ 892.14 million by 2034, rising at a compound annual growth rate (CAGR) of 8.6% from 2024 to 2034. The demand for nonspecific endonucleases is high in the pharmaceutical and biotechnology industry due to growing research in genetics and gene therapy.
The nonspecific endonuclease market provides nonspecific endonuclease kits and reagents and deals with R&D in which nonspecific endonuclease is used. Endonucleases are the group of enzymes used for cleaving DNA and RNA. These enzymes break the phosphodiester bond present in the DNA/RNA. Based on the cleavage specificity, the endonucleases can be specific or non-specific. Non-specific endonucleases break phosphodiester bonds without any sequence specificity. The enzymes are used in DNA fragmentation, nucleotide deletion, DNA repair, mRNA degradation, mRNA turnover, and gene silencing, which is why nonspecific endonucleases hold great potential in genetic engineering and gene therapies.
Because of their ability to treat uncommon or incurable diseases, their ability to be personalized, and their specificity in therapy, gene treatments are highly sought. As of 2023, the National Institutes of Health said that they have over 5,000 gene therapy experiments listed with them. Additionally, gene treatments are showing considerable promise in the treatment of genetically inherited illnesses and cancers. Suppose we are to increase worldwide access to these innovative medications. In that case, we must engage in initiatives that promote communication, education, and collaboration, just as we do in efforts to increase the efficacy, safety, and affordability of gene therapies.
The primary factors restraining the growth of the nonspecific endonuclease market during the projected period will be the unreliability of restriction enzyme products and the high costs associated with increasing nonspecific endonuclease production.
The major growth factor of the nonspecific endonuclease market is the increasing number of clinical trials. The growing research and development activities and advances in molecular biology favor clinical trials. Clinical trials are conducted to assess the safety, efficacy, and toxicity of novel products in humans. As of July 2025, 72 clinical trials are reported on the clinicaltrials.gov website related to CRISPR/Cas-9 as an intervention. (Source: ClinicalTrials.gov) These therapeutics are then approved by regulatory agencies to enhance the accessibility of advanced treatment.
North America dominated the nonspecific endonuclease market in 2023. The biotechnology industry’s presence in North America is strong, and it utilizes nonspecific endonucleases for various purposes. Apart from this, the pharmaceutical industry also uses this enzyme in R&D and the development of therapeutics. With the growing number of cancer patients, genetic disorders, and rare diseases, the demand for gene therapy is also increasing in the region, which further impacts the market positively.
The U.S. held the largest share of the nonspecific endonuclease market in 2023 due to growing R&D in pharmaceuticals and biotechnology. The key players and various organizations in the country also focus on genetic engineering for the development of novel treatment options.
Asia Pacific is expected to grow at the fastest rate during the forecast period. The nonspecific endonuclease market is growing due to increasing investments in the biotechnology industry, gene therapy, and genetic engineering. Countries like China, India, Japan, and South Korea are the main contributors. In an effort to become a global leader in the area, China has continued to make significant investments in genetic engineering research. China has made about $3.3 billion in total investments in the gene therapy area.
India ranks third among Asia Pacific's biotechnology destinations and is one of the top 12 global biotechnology locations. With a projected revenue of $130 billion in 2024, India's bioeconomy has seen a multiplication in value during the last eleven years. Growing demand on a national and worldwide scale is driving the expansion of the Indian biotechnology industry. In addition to exporting vaccines to more than 150 nations, India is a top location for clinical trials and contract production. Companies are using generics and biosimilars to reduce healthcare costs, and India has established itself as a center for providing accessible, quality, and inclusive healthcare solutions at a reasonable cost. In the worldwide biotechnology business, India holds about a 3% stake.
Europe is expected to grow at a significant CAGR in the nonspecific endonuclease market during the forecast period. The rising adoption of advanced technologies, increasing prevalence of genetic and rare disorders, and favorable government support are the major growth factors of the market in Europe. Government organizations also provide funding to support complex research activities. The burgeoning genomics sector and the increasing number of startups contribute to market growth.
The European Union launched the Genome of Europe (GoE) project to build a European reference genome that unlocks advances in medicine and benefits public health policy. The programme has a budget of almost €45 million, of which €20 million is funded under the Digital Europe Programme. (Source: European Commision) In addition, the French government invested €239 million in the 2025 French Genomic Medicine Initiative since 2016, which focuses on patients with rare diseases and cancer genetic predisposition.
By type, the 25kU segment is estimated to grow at a significant rate in the market during the forecast period. 25kU stands for the enzyme activity of the enzymes. 25kU enzyme activity is the most widely used activity for both research and industrial purposes because it provides a balance between efficiency and cost. Using enzymes of 25kU enzyme activity can be easily used in scaling up experiments, making it an ideal choice for different operations.
By application, the biological laboratory segment held a significant share of the nonspecific endonuclease market. Various biological analyses, studies, and experiments are conducted in biological laboratories. The use of nonspecific endonucleases in these laboratories is done for removal of DNA contamination, next-generation sequencing, gene synthesis, gene editing, plasmid preparation, study of DNA repair mechanism, study & development of gene therapy, and so on.
Samarth Kulkarni, Chairman and CEO of CRISPR Therapeutics, commented that the approval of CASGEVY by the European Commission is another important regulatory milestone underscoring the benefit of patients with SCD. He also said that there is a significant burden of these diseases across Europe, and the company aims to bring this therapy to patients in need. (Source: CRISPR Therapeutics)
By Type
By Application
By Region
August 2025
August 2025
August 2025
August 2025